Unknown

Dataset Information

0

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.


ABSTRACT: Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to improve relapse rate versus subcutaneous interferon beta-1a in patients who were treatment-naive (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), and to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II). Important adverse events were infusion-associated reactions, serious infections and autoimmune events. A safety monitoring program allowed for early detection and management of autoimmune events. Recommendations for the monitoring of adverse events are made. Alemtuzumab's mechanism of action, pharmacodynamics and opportunities for future research are discussed.

SUBMITTER: Hartung HP 

PROVIDER: S-EPMC4361497 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Hartung Hans-Peter HP   Aktas Orhan O   Boyko Alexey N AN  

Multiple sclerosis (Houndmills, Basingstoke, England) 20141024 1


Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to  ...[more]

Similar Datasets

| S-EPMC3593763 | biostudies-literature
| S-EPMC3807733 | biostudies-literature
| S-EPMC8581537 | biostudies-literature
| S-EPMC7750777 | biostudies-literature
| S-EPMC7296935 | biostudies-literature
| S-EPMC5109953 | biostudies-literature
| S-EPMC5794695 | biostudies-other
| S-EPMC7841472 | biostudies-literature
| S-EPMC10401910 | biostudies-literature
| S-EPMC4853056 | biostudies-literature